Quarterly revenue from Yescarta came in at $393 million, which was a 5% decline from the second quarter of last year, while ...

Even though oncology segment revenue inched up just 1 percent year over year, the firm lifted full-year expectations slightly ...

In August 2025, Hoffmann-La Roche announced a study is to compare the efficacy and safety of glofitamab in combination with ...